Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company's Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia.
"Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry," said Mark Schneyer, Executive Vice President, Chief Financial Officer. "His deep experience working within companies and on Wall Street, his strong network of relationships, and his proven expertise in building shareholder value will be instrumental as we continue to advance our global business strategy to deliver important therapeutics for central nervous system disorders."
Mr. Kildani joins Acadia most recently from Halozyme Therapeutics, where he served as Vice President, Investor Relations and Corporate Communications and helped guide the company's transition from early drug development stage to a profitable biopharmaceutical company. Prior to Halozyme, Al oversaw investor relations and business development at Vital Therapies, Inc., and investor relations at Hologic, Inc. and Gen-probe Incorporated. Prior to his transition to the life sciences industry, Al spent over a dozen years on Wall Street serving as an analyst and portfolio manager at Stark Investments, and previously as a sell-side analyst with C.E. Unterberg, Towbin and Pacific Growth Equities LLC. Mr. Kildani earned a bachelor's degree in Economics and Finance from Boston College.
"I'm excited to join Acadia during this time of transformational growth as we deliver two important and commercially available therapeutics in areas of high unmet medical need to the patient community," said Mr. Kildani. "The ongoing strength of the DAYBUE™ (trofinetide) launch, combined with our increasingly cash-flow positive NUPLAZID® (pimavanserin) franchise and our deep pipeline with upcoming data readouts position Acadia for long-term growth as we develop new therapies for patients and their families."
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID. In addition, Acadia is developing pimavanserin as a potential treatment for the negative symptoms of schizophrenia.
About DAYBUE™ (trofinetide)
Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. In animal studies, trofinetide has been shown to increase branching of dendrites and synaptic plasticity signals.1,2 More information can be found at DAYBUE.com.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson's disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia's annual report on Form 10-K for the year ended December 31, 2022, as well as Acadia's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
References
1 Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009;106(6):2029-2034.
2 Acadia Pharmaceuticals Inc., Data on file. Study Report 2566-026. 2010.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919946367/en/